Abstract:Objective: To assess the efficacy and tolerability of quetiapine in Chinese patients hospitalized with acute bipolar mania.Methods: This was a 4-week, multicenter, randomized, double-blind, lithium-controlled, parallel-group study. Secondary endpoints in the primary analysis were: response rate (>= 50% decrease from baseline in YMRS total score) and remission rate as defined using 3 criteria: YMRS total score <= 12, YMRS total score <= 12 + MADRS total score <= 8, and YMRS total score <= 8. Other measures included: change from baseline at Day 28 in YMRS, PANSS, and MADRS total score. Adverse event (AE) data were collected throughout the study.Results: 73 (94.8%) quetiapine and 62 (80.5%) lithium patients completed the study. Mean (SD) quetiapine doses for the ITT population and responders were 648.2 (111.84) mg/day and 637.5 (118.78) mg/day, respectively, while mean lithium concentrations for the ITT population and responders were 0.80 (0.28) mmol/L and 0.80 (0.22) mmol/L, respectively. Of patients who responded to quetiapine at Day 28, 88.3% were receiving 600-800 mg/day. At Day 28 YMRS response rate was significantly greater with quetiapine than lithium (77.9% vs. 59.7%, p = 0.0132), and remission rates using the 3 criteria were significantly greater with quetiapine than lithium: YMRS total score <= 12 (70.1% vs. 48.1%, p = 0.0071), YMRS <= 12 + MADRS <= 8 (70.1% vs. 48.1%; p = 0.0071), and YMRS <= 8 (51.9% vs. 32.5%; p = 0.0147). Significant decreases were observed in PANSS, YMRS, and MADRS total scores for both groups. The most common AEs experienced by patients receiving quetiapine were constipation, dizziness, diarrhea, alanine aminotransferase increase, palpitations, aspartate aminotransferase increase, pharyngolaryngeal pain, upper respiratory tract infection and dry mouth. In patients receiving lithium, the most common AEs were nausea (16.9%), constipation (13.0%), vomiting (13.0%), nasopharyngitis (11.7%), dizziness (6.5%), diarrhea (6.5%), and upper respiratory tract infection (6.5%).Conclusion: Quetiapine was shown to be clinically effective in patients with acute bipolar mania. There were side effects with quetiapine similar to those reported in other studies that included other ethnic populations of patients.

Development and pharmacokinetics evaluation of quetiapine fumarate sustained-release tablets based on hydrophilic matrix

Efficacy and Safety of Quetiapine Extended Release Monotherapy in Bipolar Depression: a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial

Study on pramipexole dihydrochloride sustained-release tablets

Efficacy of Quetiapine Monotherapy and Combination Therapy for Patients with Bipolar Depression with Mixed Features: A Randomized Controlled Pilot Study

Formulation Development of Solid Self-Nanoemulsifying Drug Delivery Systems of Quetiapine Fumarate via Hot-Melt Extrusion Technology: Optimization Using Central Composite Design

Pharmacokinetics and Tolerability of Extended-Release Quetiapine Fumarate in Han Chinese Patients with Schizophrenia

Lurasidone Versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study

Gut Microbiota in Bipolar Depression and Its Relationship to Brain Function: an Advanced Exploration

Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study

A dual strategy to improve psychotic patients’ compliance using sustained release quetiapine oral disintegrating tablets

Efficacy and Safety of Quetiapine in the Treatment of Bipolar Acute Mania: a Randomized, Double-Blind, Lithium-Controlled Multicenter Study

An Open Label, 4-Week, Randomised, Multi-Centre, Phase IV Study to Compare the Efficacy and Safety of Quetiapine Fumarate (seroqueltm) As Mono-Therapy or Adjunct to Lithium in the Treatment of Patients with Acute Mania in Bipolar Disorder

Post-marketing surveillance of quetiapine fumarate extended-release tablets in patients with bipolar depression

Response and Remission Rates in Chinese Patients with Bipolar Mania Treated for 4 Weeks with Either Quetiapine or Lithium: a Randomized and Double-Blind Study.

An Open Label, Randomised, Valproate-Controlled Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate in the Treatment of Acute Manic Patients with Bipolar Disorder

Mucoadhesive chitosan-poly (lactic- co -glycolic acid) nanoparticles for intranasal delivery of quetiapine – Development & characterization in physiologically relevant 3D tissue models

Exploring Curative Effect of Quetiapine Fumarate in the Treatment of Bipolar Affective Disorder

Comparison of oven drying and freeze drying methods for the production of fast melt films containing quetiapine fumarate

Efficacy and Safety of Quetiapine-Xr As Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression with Generalized Anxiety Disorder and Other Comorbidities: a Randomized, Placebo-Controlled Trial.

Formulation, Development, and in-vitro Evaluation of Escitalopram Fast Dissolving Tablets

Development and Evaluation of Venlafaxine Hydrochloride Tablets for Oral Drug Delivery Technology